JP4387360B2 - キマーゼ阻害剤を有効成分として含有する薬剤 - Google Patents

キマーゼ阻害剤を有効成分として含有する薬剤 Download PDF

Info

Publication number
JP4387360B2
JP4387360B2 JP2005513378A JP2005513378A JP4387360B2 JP 4387360 B2 JP4387360 B2 JP 4387360B2 JP 2005513378 A JP2005513378 A JP 2005513378A JP 2005513378 A JP2005513378 A JP 2005513378A JP 4387360 B2 JP4387360 B2 JP 4387360B2
Authority
JP
Japan
Prior art keywords
group
carbon atoms
linear
methyl
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2005513378A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2005018672A1 (ja
Inventor
秀則 浦田
直樹 長谷
直樹 土屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Pharma Ltd
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of JPWO2005018672A1 publication Critical patent/JPWO2005018672A1/ja
Application granted granted Critical
Publication of JP4387360B2 publication Critical patent/JP4387360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2005513378A 2003-08-22 2004-08-20 キマーゼ阻害剤を有効成分として含有する薬剤 Active JP4387360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003298639 2003-08-22
JP2003298639 2003-08-22
PCT/JP2004/012335 WO2005018672A1 (fr) 2003-08-22 2004-08-20 Medicament contenant un inhibiteur de chymase en tant qu'agent actif

Publications (2)

Publication Number Publication Date
JPWO2005018672A1 JPWO2005018672A1 (ja) 2006-10-19
JP4387360B2 true JP4387360B2 (ja) 2009-12-16

Family

ID=34213721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005513378A Active JP4387360B2 (ja) 2003-08-22 2004-08-20 キマーゼ阻害剤を有効成分として含有する薬剤

Country Status (8)

Country Link
US (1) US20070032466A1 (fr)
EP (1) EP1666067A4 (fr)
JP (1) JP4387360B2 (fr)
KR (1) KR20060120601A (fr)
CN (1) CN1871029A (fr)
AU (1) AU2004266536A1 (fr)
CA (1) CA2536435A1 (fr)
WO (1) WO2005018672A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
MX2011003239A (es) 2008-09-26 2011-04-28 Merck Sharp & Dohme Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
EP2348857B1 (fr) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques
MX2011004505A (es) * 2008-10-29 2011-05-31 Merck Sharp & Dohme Derivados novedosos de bencimidazol ciclico, utiles como agentes antidiabeticos.
CA2741672A1 (fr) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Nouveaux agents antidiabetiques utiles avec des derives de benzimidazole cycliques
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9540364B2 (en) 2012-08-22 2017-01-10 Merck Sharp & Dohme Corp. Benzimidazole tetrahydrofuran derivatives
WO2014031465A1 (fr) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Nouveaux dérivés d'azabenzimidazole tétrahydropyrane
US9290517B2 (en) 2012-08-22 2016-03-22 Merck Sharp & Dohme Corp. Azabenzimidazole hexahydrofuro[3,2-b]furan derivatives
ES2755087T3 (es) 2012-08-22 2020-04-21 Merck Sharp & Dohme Derivados de benzimidazol hexahidrofuro[3,2-b]furano útiles como activadores de proteína cinasa activada por AMP
US9868733B2 (en) 2012-08-22 2018-01-16 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydrofuran derivatives
EP2906040B1 (fr) 2012-08-22 2021-02-17 Merck Sharp & Dohme Corp. Nouveaux dérivés de benzimidazole tétrahydropyrane
WO2014139388A1 (fr) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques
US9067917B2 (en) 2013-03-15 2015-06-30 Janssen Pharmaceutica Nv 1,2,5-substituted benzimidazoles as FLAP modulators
US8952177B2 (en) 2013-03-15 2015-02-10 Janssen Pharmaceutica Nv 1,2,6-substituted benzimidazoles as FLAP modulators
WO2015051496A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Composés tricycliques antidiabétiques
CN105980381A (zh) * 2013-11-08 2016-09-28 拜耳医药股份有限公司 取代的尿嘧啶及其用途
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015089809A1 (fr) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Composés hétéroaryles substitués antidiabétiques
DK3102200T3 (da) * 2014-02-07 2023-05-22 Exithera Pharmaceuticals Inc Terapeutisk forbindelse og sammensætning
WO2015160772A1 (fr) * 2014-04-15 2015-10-22 Janssen Pharmaceutica Nv Modulateurs tétrahydro-benzoimidazolyles de tgr5
JP6364362B2 (ja) * 2015-02-17 2018-07-25 学校法人福岡大学 ヒトキマーゼ阻害剤および機能性食品、並びにヒトキマーゼの活性を阻害する方法
CN111902404A (zh) 2018-02-07 2020-11-06 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
TW202404601A (zh) * 2022-04-05 2024-02-01 加拿大商索科普拉健康與人類科學兩合公司 用於選擇性消退血栓性或血栓栓塞性疾病中血栓的凝乳酶抑制劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100400639B1 (ko) * 1995-04-27 2003-12-31 미쯔비시 웰 파마 가부시키가이샤 복소환식아미드화합물및그의의약용도
KR20000068354A (ko) * 1996-09-06 2000-11-25 다께다 가즈히꼬 신규 아세트아미드 유도체 및 프로테아제 저해제
EP0940400A4 (fr) * 1996-10-25 2002-10-02 Mitsubishi Pharma Corp Nouveaux composes d'amide heterocycliques et leur utilisation a des fins medicinales
TR200100047T2 (tr) * 1998-07-15 2001-10-22 Teijin Limited Tiyobenzimidazol türevleri
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
ATE349462T1 (de) * 1998-07-28 2007-01-15 Santen Pharmaceutical Co Ltd Thiazolidin-derivate
CA2341195A1 (fr) * 1998-08-20 2000-03-02 Mitsunori Waki Compositions prophylactique ou therapeutique pour les troubles circulatoires oculaire
JP2000247908A (ja) * 1999-03-01 2000-09-12 Welfide Corp かゆみ抑制剤
EP1211249A4 (fr) * 1999-07-26 2003-02-05 Santen Pharmaceutical Co Ltd Nouveaux derives de la thiazine ou de la pyrazine
JP2001114699A (ja) * 1999-08-12 2001-04-24 Santen Pharmaceut Co Ltd キマーゼ阻害作用を有する化合物を有効成分とする血管新生阻害剤
AU7962200A (en) * 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CZ301504B6 (cs) * 2000-01-17 2010-03-24 Teijin Limited Benzimidazolové deriváty
EP1167360A1 (fr) * 2000-01-17 2002-01-02 Teijin Limited Inhibiteurs de chymase humaine
US6500835B2 (en) * 2000-02-22 2002-12-31 Suntory Limited Preventive or therapeutic drugs for fibrosis containing chymase inhibitors as the active ingredient
EP1312379A4 (fr) * 2000-08-25 2004-08-25 Takeda Chemical Industries Ltd Agents de reduction du fibrinogene
JP2002138054A (ja) * 2000-08-25 2002-05-14 Takeda Chem Ind Ltd フィブリノーゲン低下剤
ATE478857T1 (de) * 2000-09-18 2010-09-15 Toa Eiyo Ltd N-substituierte benzothiophensulfonamid-derivate
AU2002233698B2 (en) * 2001-02-22 2007-11-08 Teijin Limited Benzo(b)thiophene derivative and process for producing the same
EP1298130B1 (fr) * 2001-05-07 2008-08-13 Teijin Pharma Limited Derives de 3-hydroxymethylbenzo b thiopene et procede de preparation
KR100902799B1 (ko) * 2001-08-24 2009-06-12 데이진 가부시키가이샤 키마제 저해제 및 ａｃｅ 저해제를 유효성분으로 함유하는약제
CL2004001034A1 (es) * 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
EP1666067A1 (fr) 2006-06-07
US20070032466A1 (en) 2007-02-08
AU2004266536A1 (en) 2005-03-03
CN1871029A (zh) 2006-11-29
JPWO2005018672A1 (ja) 2006-10-19
KR20060120601A (ko) 2006-11-27
EP1666067A4 (fr) 2009-07-22
CA2536435A1 (fr) 2005-03-03
WO2005018672A1 (fr) 2005-03-03

Similar Documents

Publication Publication Date Title
JP4387360B2 (ja) キマーゼ阻害剤を有効成分として含有する薬剤
KR100967070B1 (ko) 아세트산 아닐리드 유도체를 유효성분으로 하는 과활동방광 치료제
JP4173098B2 (ja) キマーゼ阻害剤及びａｃｅ阻害剤を有効成分として含有する薬剤
PL193365B1 (pl) Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz zastosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II
CN102464658B (zh) 噁唑烷酮衍生物及其制备方法和用途
BR122018015003B1 (pt) kit compreendendo composições farmacêuticas de inibidor da nep e de valsartan ou seus sais
RU2324484C2 (ru) Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
BRPI0715492A2 (pt) uso de inibidores diretos de trombina
EA006604B1 (ru) Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
JPWO2006137510A1 (ja) 脳血管障害時における出血低減剤
CN106008488A (zh) 氰基吲哚类衍生物及其制备方法和用途
JPH01224316A (ja) 医薬製剤
UA122780C2 (uk) Композиції, що містять 2-((1-(2-(4-фторфеніл)-2-оксоетил)піперидин-4-іл)метил)ізоіндолін-1-он, для лікування шизофренії
JPWO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
JPH09502727A (ja) Ｎｉｄｄｍの発症を阻止又は遅延するためのチアゾリジンジオン類の用途
KR20070085973A (ko) 수면 장애 예방 또는 치료제
CA2732018A1 (fr) Composition pharmaceutique solide
WO2002045750A1 (fr) Medicaments combines
JP2011506363A (ja) 心不全の処置および／または予防用のオキサゾリジノン類
CA3009609C (fr) Prevention et traitement de l'insuffisance cardiaque
CN110237072B (zh) 药物组合物的制备方法
JP2005515984A (ja) メトホルミンと４−オキソブタン酸の組合せを有する薬剤組成物、および糖尿病治療へのその適用
JP2008255064A (ja) 睡眠障害予防治療剤
JP2013526503A (ja) キサンチンオキシダーゼ阻害剤とアンジオテンシンｉｉ受容体アンタゴニストとの合剤およびその使用
WO2021203779A1 (fr) Composé destiné au traitement de l'hypertension artérielle pulmonaire et son application

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090421

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090619

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090908

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090930

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121009

Year of fee payment: 3